The chimeric TAC receptor co-opts the T cell receptor yielding robust anti-tumor activity without toxicity
2018 · Nature Communications · 120 citations
https://doi.org/10.1038/s41467-018-05395-y
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
52
Papers
784
Citations
9
h-index
9
i10-index
Christopher W. Helsen is an academic researcher. The author has contributed to research in topics: CAR-T cell therapy research & Monoclonal and Polyclonal Antibodies Research & Biosimilars and Bioanalytical Methods. The author has an h-index of 9, co-authored 45 publications.
Click to start Chat